 bluebird bio has had its fair share of problems over the years, but remains a pioneering gene therapy company. Last week, an FDA Advisory Committee voted unanimously in favour of approving 2 of bluebirds drugs - for Beta thalassemia and cerebral adrenoleukodystrophy. 